New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
05:55 EDTMMM, MMM, GWW, GWW, UNP, UNP, SWK, SWK, LUV, LUV, RTN, RTN, PCP, PCP, MKC, MKC, LMT, LMT, KEY, KEY, EQT, EQT, DOV, DOV, CELG, CELG, BMY, BMY, BAX, BAX, ABC, ABC, ARG, ARG, XRX, XRXCompanies reporting Before the Market Open on Thursday, January 24
Notable companies reporting before the opening bell on Thursday include 3M Co (MMM), Airgas (ARG), AmerisourceBergen (ABC), Baxter International (BAX), Bristol-Myers Squibb (BMY), Celgene (CELG), Dover (DOV), EQT (EQT), KeyCorp (KEY), Lockheed Martin (LMT), McCormick & Company (MKC), Precision Castparts (PCP), Raytheon (RTN), Southwest Airlines (LUV), Stanley Black & Decker (SWK), Union Pacific (UNP), W.W. Grainger (GWW), and Xerox (XRX).
News For MMM;ARG;ABC;BAX;BMY;CELG;DOV;EQT;KEY;LMT;MKC;PCP;RTN;LUV;SWK;UNP;GWW;XRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
December 8, 2014
10:00 EDTLUVOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Antero Resources (AR) upgraded to Buy from Neutral at Citigroup... Apache (APA) upgraded to Buy from Neutral at Citigroup... Applied Materials (AMAT) upgraded to Buy from Hold at Deutsche Bank... Arch Capital (ACGL) upgraded to Outperform from Market Perform at BMO Capital... CU Bancorp (CUNB) upgraded to Buy from Hold at Sandler O'Neill... Calpine (CPN) upgraded to Outperform from Neutral at Macquarie... Commerzbank (CRZBY) upgraded to Market Perform from Underperform at Keefe Bruyette... EastGroup Properties (EGP) upgraded to Neutral from Underperform at Credit Suisse... Enbridge Energy Management (EEQ) upgraded to Equal Weight at Morgan Stanley... Enbridge Energy (EEP) upgraded to Equal Weight from Underweight at Morgan Stanley... GasLog (GLOG) upgraded to Buy from Hold at Stifel... Hoegh LNG (HMLP) upgraded to Buy from Neutral at UBS... Illinois Tool Works (ITW) upgraded to Buy from Accumulate at Global Hunter... LaSalle Hotel (LHO) upgraded at Morgan Stanley... Lufthansa (DLAKY) upgraded to Buy from Neutral at Nomura... NASDAQ (NDAQ) upgraded to Outperform from Market Perform at Keefe Bruyette... Newfield Exploration (NFX) upgraded to Buy from Neutral at Citigroup... Omega Healthcare (OHI) upgraded to Buy from Hold at Jefferies... Orange SA (ORAN) upgraded to Conviction Buy from Neutral at Goldman... SM Energy (SM) upgraded to Outperform from Market Perform at BMO Capital... Southwest (LUV) upgraded at Goldman... TSMC (TSM) upgraded to Buy from Neutral at BofA/Merrill... United Technologies (UTX) upgraded at Bernstein... eBay (EBAY) upgraded to Buy from Hold at Stifel.
08:49 EDTDOVDover cuts FY14 adjusted EPS $4.55-$4.62 from $4.750$4.80, consensus $4.77
Subscribe for More Information
08:48 EDTDOVDover sees FY15 EPS $5.05-$5.30, consensus $5.21
Subscribe for More Information
08:47 EDTLUVSouthwest reports November 8.6B revenue passenger miles
Subscribe for More Information
07:36 EDTCELGAgios announces Celgene to extend discovery phase of collaboration to April 2016
Agios Pharmaceuticals (AGIO) announced that Celgene (CELG) has elected to extend the period of its exclusivity for an additional year to April 2016 under the global strategic collaboration agreement. The two companies have been working together since April 2010 to discover, develop and commercialize disease-altering therapies in oncology arising from Agios' cancer metabolism research platform. The terms of the collaboration extension are consistent with previously agreed upon financial terms. As a result of the extension, Celgene will maintain its exclusive option to drug candidates that emerge from Agios' cancer metabolism research platform through April 2016. Agios will receive a $20M payment. Following this extension, the discovery portion of the collaboration will expire on April 14, 2016. Under the terms of the original agreement announced in April 2010, Agios leads research, preclinical and early development efforts through Phase 1, while Celgene receives an option to obtain exclusive rights either upon IND acceptance or at the end of Phase 1, to further development and commercialize medicines emerging from Agios' cancer metabolism research. Celgene would lead and fund global development and commercialization of some of these drugs, and Agios would retain development and commercialization rights for certain drugs in the United States. On all programs, Agios is eligible to receive up to $120M in milestone-based payments as well as royalties on any sales.
07:31 EDTEQTEQT Corporation plans registration statement for EQT Midstream Partners
Subscribe for More Information
07:17 EDTCELGCelgene price target raised to $131 from $120 at Cantor
Subscribe for More Information
07:08 EDTEQTEQT Midstream Partners sees 2015 adjusted EBITDA $330M-$345M
Subscribe for More Information
07:06 EDTEQTEQT Corporation sees 2015 sales volume 575 600 Bcfe
Subscribe for More Information
07:04 EDTEQTEQT Corporation sees 2015 capital expenditures $2.5B
EQT Corporation (EQT) announced the companys 2015 capital expenditure forecast of $2.5B, excluding business development and land acquisitions. The CAPEX forecast includes $2.3B for EQT Production and $225M-$250M for EQT Midstream depending on the timing of an expected drop-down. Funding will be provided by cash generated from operations, cash-on-hand, and proceeds from midstream asset sales to EQT Midstream Partners, LP (EQM). EQTs 2015 CAPEX forecast excludes CAPEX for EQT Midstream Partners, LP, a master limited partnership controlled by EQT Corporation and consolidated in EQTs financial statements.
06:27 EDTLUVSouthwest upgraded at Goldman
As previously reported, Goldman upgraded Southwest to Buy from Neutral. The firm believes shares can continue to move higher on the strong operating environment and improving net margins. Price target raised to $55 from $44.
06:08 EDTDOVDover to host investor meeting
Subscribe for More Information
05:53 EDTBMYStocks with implied volatility movement; BSX BMY
Subscribe for More Information
05:44 EDTLUVSouthwest upgraded to Buy from Neutral at Goldman
05:35 EDTCELGCelgene REVLIMID, low-dose dexamethasone increased PFS
Subscribe for More Information
December 7, 2014
16:40 EDTCELGAgios announces new data from Ongoing Phase 1 trial of AG-221
Subscribe for More Information
14:10 EDTBMY, CELGAmerican Society of Hematology to hold a meeting
Subscribe for More Information
13:16 EDTCELGCelgene, Acceleron announced data from luspatercept phase 2 clinical trial
Subscribe for More Information
13:06 EDTBMYBMY announces positive results in Phase 1b trial evaluating Opdivo
Subscribe for More Information
December 6, 2014
09:28 EDTCELGCelgene to hold an analyst and investor event
Analyst and Investor Event being held in conjunction with the American Society of Hematology's 56th Annual Meeting in San Francisco on December 7 at 11 pm. Webcast Link
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use